Smith Anglin Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Smith Anglin Financial’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-29,050	Closed	-$243K	–	210
2025 Q1	$243K	Buy	29,050 +50	+0.2%	+$417	0.03%	177
2024 Q4	$230K	Hold	29,000	–	–	0.02%	182
2024 Q3	$241K	Hold	29,000	–	–	0.02%	172
2024 Q2	$184K	Hold	29,000	–	–	0.02%	189
2024 Q1	$176K	Hold	29,000	–	–	0.02%	191
2023 Q4	$176K	Hold	29,000	–	–	0.02%	176
2023 Q3	$122K	Hold	29,000	–	–	0.01%	170
2023 Q2	$89.9K	Sell	29,000 -1,300	-4%	-$2.77K	0.01%	168
2023 Q1	$42.1K	Buy	+30,300	New	+$60.3K	0.01%	165

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smith Anglin Financial's AMRX Position: Q2 2025 in Review

Smith Anglin Financial sold out of Amneal Pharmaceuticals (AMRX) in Q2 2025, closing a stake of 29,050 shares — an estimated $243K sold.

Smith Anglin Financial first reported a position in AMRX in Q1 2023 and held it in 9 quarters. The position peaked at $243K in Q1 2025. 241 funds tracked by Wall St. Rank hold AMRX as of Q2 2025.

Smith Anglin Financial reported no remaining Amneal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Smith Anglin Financial sold 29,050 Amneal Pharmaceuticals shares in Q2 2025, an estimated $243K.
Smith Anglin Financial first reported a position in Amneal Pharmaceuticals in Q1 2023 and held it in 9 quarters.
Smith Anglin Financial's Amneal Pharmaceuticals position peaked at $243K in Q1 2025.
241 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2025.

Based on Smith Anglin Financial's 13F filing for Q2 2025, filed 17 Jul 2025.